Aisling M. McEvoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aisling M. McEvoy has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Justin P. Turner
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University Melbourne Victoria Australia
4 shared publications - Emily Reeve
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia
3 shared publications - Aili Veronica Langford
Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
2 shared publications Cara Tannenbaum
Centre de recherche, Institut universitaire de gériatrie de Montréal, Québec
2 shared publications- Deborah V. Kelly
School of Pharmacy, Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador
2 shared publications - Kelda Newport
School of Pharmacy, Memorial University of Newfoundland, Newfoundland and Labrador
2 shared publications
Latest Publications
- 16 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (1) , 286-296
Insomnia treatment preferences of older adults and people living with dementia: A qualitative study
Background: Insomnia is common in people living with dementia and older adults. While clinical guidelines recommend non-pharmacological treatment as first-line therapy, insomnia is often managed with benzodiazepine receptor agonists (BZRAs), which carry a significant risk of medication-related harm. Objective: To explore what influences decisions to engage with pharmacological and non-pharmacological insomnia treatments among older adults, people living with dementia and their carers. Methods: Semi-structured interviews were conducted with three participant groups (people living with dementia, their carers, and older adults). The interviews were conducted and transcribed in Zoom. Participants identified and prioritized factors that influence their treatment decisions. Thematic analysis was conducted in NVivo to generate themes that described how participants’ beliefs and experiences influenced their preferences. Results: From 19 interviews with 20 participants (Median age range = 65–74 years, 37% female), 14 factors were identified. Risk of side effects (n = 10) and effectiveness (n = 7) were most commonly prioritized and frequently reported across all participant groups. Medication side effects on cognition and daytime sedation were frequent concerns. Underpinning these factors were five main themes determined from thematic analysis, including: beliefs about sleep and insomnia, treatment expectations and experiences, external influences, treatment characteristics, and barriers to treatment. Conclusions: Decisions about insomnia treatments are influenced not only by expected and/or experienced treatment effectiveness, but also by perceived risks and health beliefs. Integrating these perspectives into clinical decision-making may help reduce medication-related harm and promote safer, acceptable alternatives.
- 16 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (1) , 286-296
Insomnia treatment preferences of older adults and people living with dementia: A qualitative study
Background: Insomnia is common in people living with dementia and older adults. While clinical guidelines recommend non-pharmacological treatment as first-line therapy, insomnia is often managed with benzodiazepine receptor agonists (BZRAs), which carry a significant risk of medication-related harm. Objective: To explore what influences decisions to engage with pharmacological and non-pharmacological insomnia treatments among older adults, people living with dementia and their carers. Methods: Semi-structured interviews were conducted with three participant groups (people living with dementia, their carers, and older adults). The interviews were conducted and transcribed in Zoom. Participants identified and prioritized factors that influence their treatment decisions. Thematic analysis was conducted in NVivo to generate themes that described how participants’ beliefs and experiences influenced their preferences. Results: From 19 interviews with 20 participants (Median age range = 65–74 years, 37% female), 14 factors were identified. Risk of side effects (n = 10) and effectiveness (n = 7) were most commonly prioritized and frequently reported across all participant groups. Medication side effects on cognition and daytime sedation were frequent concerns. Underpinning these factors were five main themes determined from thematic analysis, including: beliefs about sleep and insomnia, treatment expectations and experiences, external influences, treatment characteristics, and barriers to treatment. Conclusions: Decisions about insomnia treatments are influenced not only by expected and/or experienced treatment effectiveness, but also by perceived risks and health beliefs. Integrating these perspectives into clinical decision-making may help reduce medication-related harm and promote safer, acceptable alternatives.
- Open Access
- 10 September 2026
- Published by Springer Nature in Research Square
Beyond Barriers: Developing an Optimised Workflow to Increase Home Medicines Review Uptake in Support at Home Recipients
Introduction: Home Medicines Reviews (HMRs) are a structured, multidisciplinary, government-funded service to optimise medication use and reduce medication-related harm. Despite meeting eligibility criteria for an HMR, many people receiving home care support (called the Support at Home [SAH] program) do not receive an HMR. Aim To explore enablers for the uptake of HMRs for those who receive SAH programs from a healthcare professionals’ perspective; and to create an optimised workflow model, based on these enablers, providing strategies that support increased uptake of HMRs for recipients of SAH programs. Method Six Nominal Group Technique sessions were conducted with healthcare professionals (general practitioners (GPs), pharmacists, and nurses). Participants generated, then prioritised enablers of HMR delivery, which informed an optimised workflow comprising micro (individual), meso (organisational), and macro (system) level strategies. Results Twenty-six healthcare professionals participated (GPs n = 7, pharmacists n = 7, nurses n = 11). Three enablers were consistently prioritised across all groups: systems to identify participants, healthcare professional education, and strong multidisciplinary communication. Workflow analysis identified actions at multiple levels that may improve HMR uptake: clinically focused HMR reports (micro), embedded screening tools (meso) and changes to policy to facilitate broader referral and reduce GP burden (macro). Conclusion Increasing HMR uptake requires coordinated action across individual, organisational, and system levels. GPs play a central role in HMR delivery; however, providing education to all healthcare professionals on the role they can play in supporting the process (e.g., patient identification, referral pathways, content of the written HMR) was identified as an enabler of HMR uptake. Identifying a clear patient need was important, indicating an opportunity for nurses and pharmacists to support HMR identification and referral. Embedding this shared responsibility across the healthcare system may increase HMR uptake for this vulnerable population.
- 10 September 2026
- Published by Springer Nature in Research Square
Open AccessBeyond Barriers: Developing an Optimised Workflow to Increase Home Medicines Review Uptake in Support at Home Recipients
Introduction: Home Medicines Reviews (HMRs) are a structured, multidisciplinary, government-funded service to optimise medication use and reduce medication-related harm. Despite meeting eligibility criteria for an HMR, many people receiving home care support (called the Support at Home [SAH] program) do not receive an HMR. Aim To explore enablers for the uptake of HMRs for those who receive SAH programs from a healthcare professionals’ perspective; and to create an optimised workflow model, based on these enablers, providing strategies that support increased uptake of HMRs for recipients of SAH programs. Method Six Nominal Group Technique sessions were conducted with healthcare professionals (general practitioners (GPs), pharmacists, and nurses). Participants generated, then prioritised enablers of HMR delivery, which informed an optimised workflow comprising micro (individual), meso (organisational), and macro (system) level strategies. Results Twenty-six healthcare professionals participated (GPs n = 7, pharmacists n = 7, nurses n = 11). Three enablers were consistently prioritised across all groups: systems to identify participants, healthcare professional education, and strong multidisciplinary communication. Workflow analysis identified actions at multiple levels that may improve HMR uptake: clinically focused HMR reports (micro), embedded screening tools (meso) and changes to policy to facilitate broader referral and reduce GP burden (macro). Conclusion Increasing HMR uptake requires coordinated action across individual, organisational, and system levels. GPs play a central role in HMR delivery; however, providing education to all healthcare professionals on the role they can play in supporting the process (e.g., patient identification, referral pathways, content of the written HMR) was identified as an enabler of HMR uptake. Identifying a clear patient need was important, indicating an opportunity for nurses and pharmacists to support HMR identification and referral. Embedding this shared responsibility across the healthcare system may increase HMR uptake for this vulnerable population.
- 30 September 2025
- Published by The University of Sydney Library in International Journal of Innovation in Science and Mathematics Education
- Vol. 33 (2)
Connecting student attitudes and sustainability competencies in pharmaceutical science education
Environmental and social sustainability is an increasingly significant factor for the pharmaceutical industry. Higher education programs need to equip future pharmaceutical professionals with the knowledge, skills and attitudes to effectively address sustainability problems and seize emerging opportunities. Sustainability competency (SC) frameworks may offer guidance for developing sustainability curricula, but there is little precedence for their integration into programs that do not specialise in sustainability or the environment. This study explores the application of SC frameworks for designing learning and assessment activities, and gauges student attitudes towards sustainability in a module of the Monash University Master of Pharmaceutical Science degree. A mixed methods approach involving a student attitude survey and a reflective assessment task was undertaken (11% response rate). Students discussed insights and experiences that mapped onto each of the systems thinking, problem-solving, strategic thinking, collaboration/interpersonal futures-thinking, and values thinking competencies. Of note, most students considered sustainability as being relevant for their future pharmaceutical science careers. The SC framework provided insight into student learning and gaps, as well as pedagogical design.
- 30 September 2025
- Published by The University of Sydney Library in International Journal of Innovation in Science and Mathematics Education
- Vol. 33 (2)
Connecting student attitudes and sustainability competencies in pharmaceutical science education
Environmental and social sustainability is an increasingly significant factor for the pharmaceutical industry. Higher education programs need to equip future pharmaceutical professionals with the knowledge, skills and attitudes to effectively address sustainability problems and seize emerging opportunities. Sustainability competency (SC) frameworks may offer guidance for developing sustainability curricula, but there is little precedence for their integration into programs that do not specialise in sustainability or the environment. This study explores the application of SC frameworks for designing learning and assessment activities, and gauges student attitudes towards sustainability in a module of the Monash University Master of Pharmaceutical Science degree. A mixed methods approach involving a student attitude survey and a reflective assessment task was undertaken (11% response rate). Students discussed insights and experiences that mapped onto each of the systems thinking, problem-solving, strategic thinking, collaboration/interpersonal futures-thinking, and values thinking competencies. Of note, most students considered sustainability as being relevant for their future pharmaceutical science careers. The SC framework provided insight into student learning and gaps, as well as pedagogical design.
- Open Access
- 27 July 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (1) , 207-222
Top 10 consumer and healthcare professional priorities for research in the field of quality use of medicines in people living with dementia
Background: People living with Alzheimer's disease and other types of dementia are vulnerable to medicine-related problems. More research is needed to support achieving quality use of medicines in people living with dementia. Objective: To determine the top 10 unanswered quality use of medicines questions for people living with dementia, as prioritized by Australians living with dementia, their carers, and healthcare professionals. Methods: The James Lind Alliance Priority Setting Partnership method was used. This manuscript reports the second half of the priority setting process. Using a quantitative survey, consumers (people living with dementia, their carers and family and friends) and healthcare professionals selected up to ten research questions about quality use of medicines that they felt were most important. The research questions were informed by a previous national qualitative survey and evidence checking process to identify those that were unanswered. An online workshop was then conducted with consumers and healthcare professionals to prioritize the unanswered questions, resulting in a top 10 list. Results: 171 consumers and 67 healthcare professionals completed the survey and the workshop included 17 participants. The top 10 priorities related to shared decision making, education of healthcare professionals, communication between healthcare professionals, reducing the use of unnecessary and harmful medicines, managing medicines safely at home, medicine reviews, residential aged care facilities and managing pain, behavioral changes, depression and anxiety. Conclusions: Targeting research efforts towards these identified consumer and healthcare professional priorities will ensure research funds are being directed to the most urgent areas of need in practice.
- 27 July 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (1) , 207-222
Open AccessTop 10 consumer and healthcare professional priorities for research in the field of quality use of medicines in people living with dementia
Background: People living with Alzheimer's disease and other types of dementia are vulnerable to medicine-related problems. More research is needed to support achieving quality use of medicines in people living with dementia. Objective: To determine the top 10 unanswered quality use of medicines questions for people living with dementia, as prioritized by Australians living with dementia, their carers, and healthcare professionals. Methods: The James Lind Alliance Priority Setting Partnership method was used. This manuscript reports the second half of the priority setting process. Using a quantitative survey, consumers (people living with dementia, their carers and family and friends) and healthcare professionals selected up to ten research questions about quality use of medicines that they felt were most important. The research questions were informed by a previous national qualitative survey and evidence checking process to identify those that were unanswered. An online workshop was then conducted with consumers and healthcare professionals to prioritize the unanswered questions, resulting in a top 10 list. Results: 171 consumers and 67 healthcare professionals completed the survey and the workshop included 17 participants. The top 10 priorities related to shared decision making, education of healthcare professionals, communication between healthcare professionals, reducing the use of unnecessary and harmful medicines, managing medicines safely at home, medicine reviews, residential aged care facilities and managing pain, behavioral changes, depression and anxiety. Conclusions: Targeting research efforts towards these identified consumer and healthcare professional priorities will ensure research funds are being directed to the most urgent areas of need in practice.
- Open Access
- 7 May 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (9) , 2905-2913
Deprescribing Benzodiazepine Receptor Agonists in Older Adults and People With Cognitive Impairment: A Systematic Review
Background: Benzodiazepine receptor agonists (BZRAs) (benzodiazepines and z‐drugs) may provide limited benefits in the management of insomnia when used short‐term. However, they increase the risk of harms including falls, fractures, hospitalizations, and cognitive impairment. Deprescribing (cessation) of BZRAs may be beneficial for older adults and people living with cognitive impairment as they are at heightened risk of adverse events. This review investigated the effects of patient‐directed, non‐pharmacological interventions to support deprescribing of BZRAs used for insomnia in older adults and people living with cognitive impairment.Methods: Embase, CENTRAL, Scopus, and Medline were searched in January 2024 with no publication date restrictions. Screening, data extraction, and risk of bias assessments (ROB2 for randomized studies, ROBINS‐I for non‐randomized studies) were conducted independently by two authors. Outcomes of interest included the proportion of participants who ceased BZRAs, reduction in BZRAs, switching to another medication, sleep outcomes, and clinical outcomes. Studies were included if they investigated BZRA deprescribing in older adults (≥ 65 years) or people living with cognitive impairment.Results: Seventeen reports analyzing 16 studies in hospital, community, and aged care settings were included. BZRA cessation rates ranged between 23% to 72% for written education (n = 6); 14% to 57% for combined written and verbal education (n = 5); and 9% to 100% for multi‐component interventions (n = 6). One report investigated a BZRA deprescribing educational intervention in people with cognitive impairment and found comparable effectiveness to participants without cognitive impairment. Most studies were at a high risk of bias.Conclusions: Patient‐directed interventions led to BZRA cessation, although there was significant variability between studies. It is unknown if all interventions examined are similarly effective for people living with cognitive impairment. Further research investigating approaches to deprescribing BZRAs in older adults or people with cognitive impairment is required.
- 7 May 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (9) , 2905-2913
Open AccessDeprescribing Benzodiazepine Receptor Agonists in Older Adults and People With Cognitive Impairment: A Systematic Review
Background: Benzodiazepine receptor agonists (BZRAs) (benzodiazepines and z‐drugs) may provide limited benefits in the management of insomnia when used short‐term. However, they increase the risk of harms including falls, fractures, hospitalizations, and cognitive impairment. Deprescribing (cessation) of BZRAs may be beneficial for older adults and people living with cognitive impairment as they are at heightened risk of adverse events. This review investigated the effects of patient‐directed, non‐pharmacological interventions to support deprescribing of BZRAs used for insomnia in older adults and people living with cognitive impairment.Methods: Embase, CENTRAL, Scopus, and Medline were searched in January 2024 with no publication date restrictions. Screening, data extraction, and risk of bias assessments (ROB2 for randomized studies, ROBINS‐I for non‐randomized studies) were conducted independently by two authors. Outcomes of interest included the proportion of participants who ceased BZRAs, reduction in BZRAs, switching to another medication, sleep outcomes, and clinical outcomes. Studies were included if they investigated BZRA deprescribing in older adults (≥ 65 years) or people living with cognitive impairment.Results: Seventeen reports analyzing 16 studies in hospital, community, and aged care settings were included. BZRA cessation rates ranged between 23% to 72% for written education (n = 6); 14% to 57% for combined written and verbal education (n = 5); and 9% to 100% for multi‐component interventions (n = 6). One report investigated a BZRA deprescribing educational intervention in people with cognitive impairment and found comparable effectiveness to participants without cognitive impairment. Most studies were at a high risk of bias.Conclusions: Patient‐directed interventions led to BZRA cessation, although there was significant variability between studies. It is unknown if all interventions examined are similarly effective for people living with cognitive impairment. Further research investigating approaches to deprescribing BZRAs in older adults or people with cognitive impairment is required.
- Open Access
- 6 May 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 157 (4) , 164-170
How to change workflow to enhance implementation of professional services in community pharmacies: A deprescribing case study
- 6 May 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 157 (4) , 164-170
Open AccessHow to change workflow to enhance implementation of professional services in community pharmacies: A deprescribing case study
- Open Access
- 13 April 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 157 (3) , 133-142
Strategies to guide the successful implementation of deprescribing in community practice: Lessons learned from the front line
Background: Sustainable implementation of new professional services into clinical practice can be difficult. In 2019, a population-wide initiative called SaferMedsNL was implemented across the province of Newfoundland and Labrador (NL), to promote appropriate medication use. Two evidence-based interventions were adapted to the context of NL to promote deprescribing of proton pump inhibitors and sedatives. The objective of this study was to identify and prioritize which actions supported the implementation of deprescribing in community practice for pharmacists, physicians and nurse practitioners across the province. Methods: Community pharmacists, physicians and nurse practitioners were invited to participate in virtual focus groups. Nominal Group Technique was used to elicit responses to the question: “What actions support the implementation of deprescribing into the daily workflow of your practice?” Participants prioritized actions within each group while thematic analysis permitted comparison across groups. Results: Five focus groups were held in fall 2020 involving pharmacists ( n = 11), physicians ( n = 7) and nurse practitioners ( n = 4). Participants worked in rural ( n = 10) and urban ( n = 12) settings. The different groups agreed on what the top 5 actions were, with the top 5 receiving 68% of the scores: (1) providing patient education, (2) allocating time and resources, (3) building interprofessional collaboration and communication, (4) fostering patient relationships and (5) aligning with public awareness strategies. Conclusion: Pharmacists, physicians and nurse practitioners identified similar actions that supported implementing evidence-based deprescribing into routine clinical practice. Sharing these strategies may help others embed deprescribing into daily practice and assist the uptake of medication appropriateness initiatives by front-line providers. Can Pharm J (Ott) 2024;157:xx-xx.
- 13 April 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
- Vol. 157 (3) , 133-142
Open AccessStrategies to guide the successful implementation of deprescribing in community practice: Lessons learned from the front line
Background: Sustainable implementation of new professional services into clinical practice can be difficult. In 2019, a population-wide initiative called SaferMedsNL was implemented across the province of Newfoundland and Labrador (NL), to promote appropriate medication use. Two evidence-based interventions were adapted to the context of NL to promote deprescribing of proton pump inhibitors and sedatives. The objective of this study was to identify and prioritize which actions supported the implementation of deprescribing in community practice for pharmacists, physicians and nurse practitioners across the province. Methods: Community pharmacists, physicians and nurse practitioners were invited to participate in virtual focus groups. Nominal Group Technique was used to elicit responses to the question: “What actions support the implementation of deprescribing into the daily workflow of your practice?” Participants prioritized actions within each group while thematic analysis permitted comparison across groups. Results: Five focus groups were held in fall 2020 involving pharmacists ( n = 11), physicians ( n = 7) and nurse practitioners ( n = 4). Participants worked in rural ( n = 10) and urban ( n = 12) settings. The different groups agreed on what the top 5 actions were, with the top 5 receiving 68% of the scores: (1) providing patient education, (2) allocating time and resources, (3) building interprofessional collaboration and communication, (4) fostering patient relationships and (5) aligning with public awareness strategies. Conclusion: Pharmacists, physicians and nurse practitioners identified similar actions that supported implementing evidence-based deprescribing into routine clinical practice. Sharing these strategies may help others embed deprescribing into daily practice and assist the uptake of medication appropriateness initiatives by front-line providers. Can Pharm J (Ott) 2024;157:xx-xx.